Abstract
BACKGROUND: Various studies have evaluated the significance of phosphohistone-H3 (PHH3) expression in cancer patients, but controversy over its reliability remains. We conducted a meta-analysis to summarize the prognostic relevance of PHH3 expression in cancer patients. PATIENTS AND METHODS: Nineteen studies, including 4803 patients, were identified by searching PubMed, Web of Science, Embase, and Cochrane Library. The correlation of PHH3 expression level with overall survival (OS), disease-free survival, and recurrence-free survival was analyzed. RESULTS: Overall, the results suggest that high expression of PHH3 can predict a poor OS (HR=2.66, 95% CI=1.74-4.08, P<0.001), disease-free survival (HR=3.40, 95% CI=1.47-7.87, P=0.004), and recurrence-free survival (HR=2.80, 95% CI=1.61-4.85, P<0.001) in cancer patients. The subgroup analysis showed that highly expressed PHH3 was significantly related to breast cancer (HR=5.66, 95% CI=2.72-11.78, P<0.001) and urogenital tumors (HR=3.01, 95% CI=1.78-5.09, P<0.001). Furthermore, no significant difference was found between Asian (HR=1.98, 95% CI=1.08-3.63, P=0.026) and Caucasian populations (HR=3.01, 95% CI=1.87-4.85, P<0.001) regarding OS and PHH3 expression. CONCLUSION: This meta-analysis indicates that high expression of PHH3 may serve as a biomarker for poor prognosis in patients with cancer.